Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224029 | 0.85 | CHRNB2 (0.53) | CHRNB2CHRNA4TSHRMAPK1TDP1 | |
| SCHEMBL15295402 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4ESMN1; SMN2TSHRMAPK1 | |
| SCHEMBL13462940 | 0.84 | MAPK1 (0.60) | MAPK1 | |
| SCHEMBL16301357 | 0.84 | LMNA (0.68) | ALDH1A1SMN1; SMN2TDP1SLC6A2SLC6A4 | |
| SCHEMBL10224093 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4MAPK1TDP1 | |
| SCHEMBL8057463 | 0.80 | ALDH1A1 (0.59) | ALDH1A1KDM4ESMN1; SMN2TSHRMAPK1 | |
| SCHEMBL10235855 | 0.79 | TSHR (0.52) | CHRNB2CHRNA4TSHRMAPK1TDP1 | |
| SCHEMBL10799020 | 0.78 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2TSHRMAPK1 | |
| SCHEMBL4487459 | 0.78 | KDM4E (0.68) | ALDH1A1KDM4ESMN1; SMN2TSHRMAPK1 | |
| SCHEMBL13462936 | 0.78 | LTA4H (0.55) | ALDH1A1KDM4ESMN1; SMN2TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | CHRNB2 3321/4885CHRNA4 3917/4885ALDH1A1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.